New heart failure drug passes early safety check
NCT ID NCT05328752
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 26 times
Summary
This early-stage study tested a new drug called XXB750 in 27 adults with chronic heart failure and reduced heart pumping ability. The main goal was to check if the drug is safe and tolerable. Participants received either the drug or a placebo, and researchers monitored for side effects and how the drug moves through the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE WITH REDUCED EJECTION FRACTION (HFREF) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Fairview Health Services .
Saint Paul, Minnesota, 55102, United States
-
Jacksonville Ctr for Clin Rea Main Centre
Jacksonville, Florida, 32216, United States
-
Nature Coast Clinical Research LLC
Inverness, Florida, 34452, United States
-
Novartis Investigative Site
Groningen, 9713 GZ, Netherlands
Conditions
Explore the condition pages connected to this study.